Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1991 1
1992 2
1993 1
1994 3
1995 1
1998 2
1999 5
2000 3
2001 5
2002 2
2004 3
2005 2
2006 2
2007 1
2010 3
2011 4
2015 2
2016 3
2017 1
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Results by year
Filters applied: . Clear all
Page 1
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.
Besarab A, Chernyavskaya E, Motylev I, Shutov E, Kumbar LM, Gurevich K, Chan DT, Leong R, Poole L, Zhong M, Saikali KG, Franco M, Hemmerich S, Yu KH, Neff TB. Besarab A, et al. Among authors: hemmerich s. J Am Soc Nephrol. 2016 Apr;27(4):1225-33. doi: 10.1681/ASN.2015030241. Epub 2015 Oct 22. J Am Soc Nephrol. 2016. PMID: 26494833 Free PMC article. Clinical Trial.
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, Poole L, Saikali KG, Saha G, Hemmerich S, Szczech L, Yu KH, Neff TB. Provenzano R, et al. Among authors: hemmerich s. Am J Kidney Dis. 2016 Jun;67(6):912-24. doi: 10.1053/j.ajkd.2015.12.020. Epub 2016 Feb 2. Am J Kidney Dis. 2016. PMID: 26846333 Free article. Clinical Trial.
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
Chen N, Qian J, Chen J, Yu X, Mei C, Hao C, Jiang G, Lin H, Zhang X, Zuo L, He Q, Fu P, Li X, Ni D, Hemmerich S, Liu C, Szczech L, Besarab A, Neff TB, Peony Yu KH, Valone FH. Chen N, et al. Among authors: hemmerich s. Nephrol Dial Transplant. 2017 Aug 1;32(8):1373-1386. doi: 10.1093/ndt/gfx011. Nephrol Dial Transplant. 2017. PMID: 28371815 Free PMC article. Clinical Trial.
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, Aiello JR, Novak JE, Lee T, Leong R, Roberts BK, Saikali KG, Hemmerich S, Szczech LA, Yu KH, Neff TB. Provenzano R, et al. Among authors: hemmerich s. Clin J Am Soc Nephrol. 2016 Jun 6;11(6):982-91. doi: 10.2215/CJN.06890615. Epub 2016 Apr 19. Clin J Am Soc Nephrol. 2016. PMID: 27094610 Free PMC article. Clinical Trial.
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, Leong R, Hemmerich S, Yu KH, Neff TB. Besarab A, et al. Among authors: hemmerich s. Nephrol Dial Transplant. 2015 Oct;30(10):1665-73. doi: 10.1093/ndt/gfv302. Epub 2015 Aug 3. Nephrol Dial Transplant. 2015. PMID: 26238121 Free PMC article. Clinical Trial.
Sulfotransferase structural biology and inhibitor discovery.
Rath VL, Verdugo D, Hemmerich S. Rath VL, et al. Among authors: hemmerich s. Drug Discov Today. 2004 Dec 1;9(23):1003-11. doi: 10.1016/S1359-6446(04)03273-8. Drug Discov Today. 2004. PMID: 15574316 Review.
43 results